About Cancer Focus Fund
Cancer Focus Fund is a venture capital firm founded in 2019. It is primarily based out of Houston, United States. As of Jan 2026, Cancer Focus Fund has invested in 8 companies. It primarily invests in Series A round in Israel based startups. Its investments are spread across Life Sciences sector. Most recently it participated in the $***** Series A round of Starget Pharma Overall, Cancer Focus Fund portfolio has seen 1 IPO, namely Mereo BioPharma. A lot of funds co-invest with Cancer Focus Fund, with names like aMoon sharing a substantial percentage of its portfolio. Cancer Focus Fund has team of 23 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A & Series C
Portfolio IPOs
Deals in last 12 months
Cancer Focus Fund's List of Top Investments
Cancer Focus Fund has a portfolio of 8 companies. Their most notable investments are in Nectin Therapeutics and March Biosciences.Their portfolio spans across Israel, United States, Germany and 2 more locations. They have invested in Life Sciences, across Series A, Series C stages. Here is the list of top investments by Cancer Focus Fund:
Developer of targeted radiopharmaceuticals technologies to treat solid tumors. The company's research is in the development of molecules that serve as a vector for the targeted transfer of radioactive isotopes to cancerous tumors for diagnosis and targeted treatment of cancer.
Key facts about Starget Pharma
- Founded Year: 2019
- Location: Ramat Hasharon (Israel)
- Stage: Series A
- Total Funding till date: $33.1M
- Employee Count: 20 as on Aug 31, 2026
- Investors: Cancer Focus Fund, Ilex Medical and 2 Others
- Latest Funding Round: Series A, Jan 20, 2026, $*****
- Highlight: Editors' Pick
Developer of therapeutics for cancer and rare diseases. The company's pipeline includes Etigilimab for metastatic solid tumors, Alvelestat for the treatment of severe Alpha-1 Antitrypsin Deficiency and COVID-19, Setrusumab for the treatment of Osteogenesis Imperfecta, Navicixizumab for the treatment of platinum-resistant ovarian cancer, Acumapimod for the treatment of acute exacerbations of chronic obstructive pulmonary disease, and Leflutrozole for the treatment of male infertility associated with hypogonadotropic hypogonadism.
Key facts about Mereo BioPharma
- Founded Year: 2015
- Location: London (United Kingdom)
- Annual Revenue: $0 - $1M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $119M
- Employee Count: 51 as on Mar 31, 2026
- Investors: Kreos Capital, Boxer Capital and 12 Others
- Latest Funding Round: Post IPO, Jun 04, 2020, $*****
- Highlight: Public
Developer of immunotherapies targeting resistance mechanisms in solid tumor cancers. These treatments aim to overcome immune exclusion by dismantling barriers that prevent immune cells from accessing and destroying tumor tissue. The therapeutic approach involves blocking inhibitory signals and modifying the tumor microenvironment to facilitate immune cell infiltration. The pipeline includes multifunctional antibodies and prodrugs designed to restore anti-tumor immunity in patients with solid tumors.
Key facts about ImmunoGenesis
- Founded Year: 2019
- Location: Houston (United States)
- Stage: Series C
- Total Funding till date: $44.4M
- Employee Count: 15 as on Aug 31, 2026
- Investors: Reimagined Ventures, Adit Ventures and 4 Others
- Latest Funding Round: Series C, Mar 18, 2024, $*****
- Highlight: Editors' Pick
Developer of CAR-T cell therapies for malignancies. It offers a ead asset, MB-105 which is designed to treat relapse/refractory T-cell malignancies which include leukemia, lymphoma, and others. It also has MB-107, MB-112, and MB-301 for multiple cancers.
Key facts about March Biosciences
- Founded Year: 2022
- Location: Houston (United States)
- Stage: Series A
- Total Funding till date: $33.2M
- Employee Count: 25 as on Aug 31, 2026
- Investors: 4Bio Capital, Mission BioCapital and 11 Others
- Latest Funding Round: Grant (prize money), Jul 21, 2025, $*****
- Highlight: Editors' Pick
5. KAHR
Developer of immune therapeutics to treat cancer. The company's product candidates include DSP107 SIRPα-41BBL, DSP105 PD1-41BBL, and TSPs TIGIT/LILRB/SIGLEC used for the treatment of solid tumour. The company has developed its proprietary MIRP (Multifunctional Immune Recruitment Protein) technology for the discovery of immuno-recruitment drugs. It is used to target the immune checkpoints for unmasking cancer camouflage mechanisms.
Key facts about KAHR
- Founded Year: 2005
- Location: Jerusalem (Israel)
- Stage: Series D
- Total Funding till date: $58.5M
- Investors: BVF Partners, DAFNA Capital Management and 14 Others
- Latest Funding Round: Series D, Nov 17, 2022, $*****
Cancer Focus Fund's Year-on-Year Investment Trends
Cancer Focus Fund has invested in 8 companies over the last 5 years, with an average of 1 new investment annually in the last 5 years. As of Jan 2026, it has made 1 investment in this year. Its most recent first time investment was in Starget Pharma and most recent follow-on round was in Starget Pharma.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 1 | 1 |
2025 | 0 | 0 | 0 |
2024 | 2 | 1 | 3 |
2023 | 1 | 0 | 1 |
2022 | 1 | 1 | 2 |
2021 | 1 | 0 | 1 |
Cancer Focus Fund's Investments by Stage
Cancer Focus Fund has made 4 investments in Series A stage with an average round size of $4.97M and 1 investment in Series C stage with an average round size of $46.5M.Stage of entry | No. of Investments |
|---|---|
Series A | 4 |
Series C | 1 |
Note: We have considered here, only first round of investments
Cancer Focus Fund's Investments by Sector
Cancer Focus Fund has a portfolio focused on Life Sciences. Notably, it has invested in 7 Enterprise (B2B) companies and 7 Tech companies.Cancer Focus Fund's Investments by Geography
Cancer Focus Fund has made most investments in Israel (3), followed by Germany where it has made 1 investment.Country | No. of Investments |
|---|---|
Israel | 3 |
Germany | 1 |
United States | 1 |
Note: We have considered here, only first round of investments
Cancer Focus Fund's recent investments
Cancer Focus Fund has made 1 investments in 2026 so far - Starget Pharma.Here are the most recent investments by Cancer Focus Fund:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 20, 2026 | Israel | Series A | 1387 | [+2] | |
Oct 31, 2024 | Israel | Series A | 7184 | - | |
Oct 07, 2024 | United States | Series A | 2421 | [+10] | |
Mar 21, 2024 | Germany | Series A | 7215 | - | |
Nov 09, 2023 | United States | Series A | 8008 | - |
IPOs and Publicly Listed companies in Cancer Focus Fund's Portfolio
1 of Cancer Focus Fund's portfolio company became public - Mereo BioPharma. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Apr 2019 at marketcap of undefinedHere are Cancer Focus Fund's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 26, 2019 | - | - | 2100 |
Team profile of Cancer Focus Fund
Cancer Focus Fund has a team of 23 members including 1 Partner and 1 Principal located in United States. Cancer Focus Fund's team does not sit on the board of any company as of now.Co-investors of Cancer Focus Fund
Over the past 5 years, 36 investors have co-invested in Cancer Focus Fund's portfolio companies. This includes funds and angels.
- Invested before Cancer Focus Fund: Ilex Medical, Europa and 6 others have invested in rounds before Cancer Focus Fund. There is 1 company where Ilex Medical has invested before Cancer Focus Fund and 1 company where Europa has invested before Cancer Focus Fund.
- Top Co-investors of Cancer Focus Fund: 9 investors entered a company along with Cancer Focus Fund. These include investors like aMoon (1 company).
- Invested after Cancer Focus Fund: A total of 19 investors have invested in Cancer Focus Fund's portfolio after their investments. Top Investors include Myeloma Investment Fund (2 companies), BRF (1 company) and Louisiana Growth Fund (1 company).
Recent News related to Cancer Focus Fund
•
•
March Biosciences: $28.4 Million (Series A) Raised To Combat Cancers And Other DiseasesPulse 2.0•Nov 08, 2024•March Biosciences, Mission BioCapital, 4Bio Capital, KdT Ventures and 8 others
•
Starget Pharma Secures $5.1M for AI-Powered Targeted Radiotherapy for CancerHIT Consultant•Nov 01, 2024•Starget Pharma, Cancer Focus Fund, MD Anderson
•
•
•
•
•
•
•
